Clinical InvestigationThe Cost of Medical Management in Advanced Heart Failure During the Final Two Years of Life
Section snippets
Study Population
This study analyzes cost and resource use related to the medical treatment of advanced heart failure and ESHF. The study population includes Medicare beneficiaries enrolled in the REMATCH trial and randomized to MM.9 Among this group (n = 61), 47 patients had detailed costing data from the Centers for Medicare and Medicaid Services (CMS). Patients eligible for REMATCH included adults with chronic ESHF (Class IV) and contraindications to transplantation; eligibility criteria, including detailed
Study Population
The study population was predominantly male (84%), 16% of patients were of Hispanic or African American origin, and the majority (71%) had ischemic cardiomyopathy (Table 1). The mean age of death was 70.4 years (±7.06). The adjudicated cause of death for 96% of patients was progression of heart failure.
Cost
The mean total cost of medical therapy per patient for chronic ESHF during the final 2 years of life was $156,168.52 (Table 2). The mean total costs by quarter increased (P < .01) 4.9-fold from
Discussion
With more than 95% of patients with advanced heart failure treated with MM alone, a better understanding of resource use in this population will allow greater insights into the economics of heart failure therapy. To characterize cost and resource use of patients with advanced heart failure as they progress to death, this study used detailed, comprehensive, and audited data collected from a small but well-characterized population of patients with heart failure. These patients were managed with
Conclusions
This current economic analysis extends on previous findings by demonstrating that medical therapy in advanced heart failure and ESHF is associated with significant costs and resource consumption. The mean total cost of medical therapy per patient for patients with advanced heart failure during the final 2 years of life was estimated to be $156,168. Costs and resource use in patients with advanced heart failure increased as death approached, with more than 50% of the total costs incurred in the
Acknowledgments
We thank the REMATCH Investigators, Cuiling Wang, PhD, and Lopa Gupta, MPH, for assistance with the preparation of this article.
References (34)
- et al.
Proportion of patients in a congestive heart failure care management program meeting criteria for cardiac resynchronization therapy
Am J Cardiol
(2004)et al.Heart failure: what proportion of patients satisfy the electrocardiographic criteria for cardiac resynchronization therapy?
Indian Heart J
(2003)et al.Indications for multisite pacing in patients with heart failure
Am J Cardiol
(2001)et al.How many people with heart failure are appropriate for biventricular resynchronization?
Eur Heart J
(2000)et al.Prevalence of potential candidates for biventricular pacing among patients with known coronary artery disease: a prospective registry from a single center
Pacing Clin Electrophysiol
(2000)et al.Biventricular pacing in patients with ICD: how many patients are possible candidates?
Thorac Cardiovasc Surg
(2002)et al.How many patients with dilated cardiomyopathy may potentially benefit from cardiac resynchronization therapy?
Pacing Clin Electrophysiol
(2003)et al.Implications of cardiac resynchronization therapy and prophylactic defibrillator implantation among patients eligible for heart transplantation
Am J Cardiol
(2004) - et al.
Cardiac resynchronization therapy: helpful now in selected patients with CHF
Circulation
(2004) - et al.
Trajectory of end-stage heart failure: the influence of technology and implications for policy change
Perspect Biol Med
(2006) American Heart Association. Heart disease and stroke statistics—2005 update
(2005)- et al.
Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH
Circulation
(2004) - American Heart Association. New heart failure guidelines stress early diagnosis and treatment. Available at:...
- et al.
The economic impact of heart failure in the United States time for a different approach
J Heart Lung Transplant
(1994) - et al.
Complexity and cost of multi-drug regimens of older patients hospitalized for heart failure
Arch Intern Med
(2005) Cost of heart failure to the healthcare system
Am J Manag Care
(1998)- et al.
The 2002/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure
Can J Cardiol
(2003)
The economic burden of heart failure
Clin Cardiol
Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term mechanical left ventricular assistance for end-stage heart failure
N Engl J Med
American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure); International Society for Heart and Lung Transplantation; Heart Failure Society of America. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Circulation
A Wilcoxon-type test for trend
Stat Med
Burden of pancreatic cancer and disease progression: economic analysis in the US
Oncology
The cost of treating pancreatic cancer—a cohort study based on patients' records from four hospitals in Sweden
Acta Oncol
Cited by (0)
Presented at the 2006 American Heart Association Scientific Sessions, November 12 to 15, 2006, Chicago, Illinois.
The REMATCH trial was supported, in part, by a cooperative agreement (HL-53986) funded by the National Heart Lung and Blood Institute of the National Institutes of Health, Bethesda, Maryland, and Thoratec Corporation, Pleasanton, California. Additional funding for the routine costs of clinical care associated with the trial was made available by the Center for Medicare and Medicaid Services and by the participating clinical centers. Reprint requests: Mark J. Russo, MD, MS, New York-Presbyterian Hospital/Columbia, Milstein Hospital Bldg, Room 7-435 GN, 177 Fort Washington Avenue, New York, NY 10032.